Ken Griffin Cerevel Therapeutics Holdings, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $34 Million - $37.3 Million	871,933 Added 1039.44%	955,818 $39.1 Million
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $6.94 Million - $7.34 Million	-169,747 Reduced 66.93%	83,885 $3.55 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $2.08 Million - $4.36 Million	102,704 Added 68.05%	253,632 $10.8 Million
Q3 2023 Nov 14, 2023	BUY	$20.26 - $31.91 $1.32 Million - $2.08 Million	65,049 Added 75.74%	150,928 $3.29 Million
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $1.23 Million - $1.82 Million	51,446 Added 149.41%	85,879 $2.73 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $689,917 - $1.07 Million	30,233 Added 719.83%	34,433 $839,000
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $1.55 Million - $1.96 Million	-61,221 Reduced 93.58%	4,200 $132,000
Q3 2022 Nov 14, 2022	SELL	$25.5 - $41.42 $10.2 Million - $16.6 Million	-400,613 Reduced 85.96%	65,421 $1.85 Million
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $9.26 Million - $16.7 Million	448,943 Added 2626.78%	466,034 $12.3 Million
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $7.67 Million - $11.5 Million	-326,353 Reduced 95.02%	17,091 $598,000
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $6.98 Million - $10.7 Million	-238,871 Reduced 41.02%	343,444 $11.1 Million
Q3 2021 Nov 15, 2021	SELL	$21.26 - $38.85 $3.61 Million - $6.6 Million	-169,850 Reduced 22.58%	582,315 $17.2 Million
Q2 2021 Aug 16, 2021	SELL	$12.56 - $29.69 $5.96 Million - $14.1 Million	-474,564 Reduced 38.69%	752,165 $19.3 Million
Q1 2021 May 17, 2021	SELL	$12.37 - $17.74 $1.92 Million - $2.75 Million	-154,827 Reduced 11.21%	1,226,729 $16.8 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $13.6 Million - $25.2 Million	1,381,556 New	1,381,556 $22.9 Million

Others Institutions Holding CERE

# of Institutions

Shares Held

5.93M

Call Options Held

27.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account